Show simple item record

dc.contributor.authorMontague, E
dc.contributor.authorHockenhull, Kimberley
dc.contributor.authorLamarca, Angela
dc.contributor.authorAl-Sayed, Tamer
dc.contributor.authorHubner, Richard A
dc.date.accessioned2019-10-07T15:16:41Z
dc.date.available2019-10-07T15:16:41Z
dc.date.issued2019en
dc.identifier.citationMontague E, Hockenhull K, Lamarca A, Al-Sayed T, Hubner RA. Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis. BMJ Case Rep. 2019 Aug 30;12(8).en
dc.identifier.pmid31473631en
dc.identifier.doi10.1136/bcr-2018-227987en
dc.identifier.urihttp://hdl.handle.net/10541/622190
dc.description.abstractParaneoplastic glomerular disease is an increasingly well-recognised entity, and a wide range of both solid and haematological malignancies have been implicated. The most common glomerular disease associated with cancer is membranous nephropathy. Only a few case reports have described an association between neuroendocrine tumours (NETs) and glomerulonephritis and only one paediatric case in relation to minimal change disease. A 76-year-old woman with a well-differentiated duodenal NET presented with nephrotic syndrome and renal biopsy was suggestive of minimal change glomerulonephritis. Standard therapy with corticosteroids brought little benefit, but a dramatic improvement was seen following initiation of systemic anticancer therapy with lanreotide, a somatostatin analogue. Less than 1?month after initiation of lanreotide, the patient was no longer in a nephrotic state, and after a further 2 months of follow-up had shown no sign of relapse.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1136/bcr-2018-227987en
dc.titleDuodenal neuroendocrine tumour associated with minimal change glomerulonephritisen
dc.typeArticleen
dc.contributor.departmentMedical Oncology, Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalBMJ Case Reportsen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record